Annual report pursuant to Section 13 and 15(d)

Fair Value Measurement

v3.8.0.1
Fair Value Measurement
12 Months Ended
Dec. 31, 2017
Fair Value Disclosures [Abstract]  
Fair Value Disclosures [Text Block]
18.
Fair Value Measurement
 
Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows:
 
Level 1:
Observable prices in active markets for identical assets and liabilities.
 
Level 2:
Observable inputs other than quoted prices in active markets for identical assets and liabilities.
 
Level 3:
Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
 
Impairment
 
Goodwill and other indefinite-lived intangible assets are tested for impairment annually, at the end of the fourth quarter of each fiscal year, and between annual tests if an event occurs or circumstances change that would indicate it is more likely than not that the carrying amount may be impaired. Additionally, the Company continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. The factors used to determine fair value are subject to management’s judgement and expertise and include, but are not limited to, the present value of future cash flows, net of estimated operating costs, internal forecasts, anticipated capital expenditures and various discount rates commensurate with the risk and current market conditions associated with realizing the expected cash flows projected. These assumptions represent Level 3 inputs. Impairment of the Company’s goodwill for the year ended December 31, 2017 was $10.3 million. Impairment of the Company’s goodwill and MIST Therapy tradename for the year ended December 31, 2016 was $10.9 million.
 
Warrant Liabilities
 
On December 31, 2016, the Company recomputed the fair value of its warrant liability of outstanding warrants to purchase an aggregate of 81,628 shares of common stock as $20,000 using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of 65.74%-72.16%, risk-free rate of 0.85%-1.47%, expected term of 0.86-3.41 years, and expected dividends of 0.00%. The Company recorded a gain on the change in fair value of these warrant liabilities of $841,000 during the year ended December 31, 2016.
 
The Company amended and restated the Warrant on each of October 25, 2016, January 26, 2017, March 7, 2017 and April 6, 2017. In addition, on June 1, 2017, the Company further amended the amended and restated Warrant. The amended and restated Warrant, as amended, is exercisable for 210,000 shares of the Company’s common stock at an exercise price of $4.70 per share. See Note 12 – Debt for additional details. In connection with the amendments of January, March, April and June 2017, the Company recomputed the fair value of the original warrant and amended warrant using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of 65.33%-78.98%, risk-free rate of 1.49%-1.95%, expected term of 3.34-5.00 years, and expected dividends of 0.00%. As a result, the Company recorded warrant modification expense of $803,000 during the year ended December 31, 2017, which represents the incremental value of the amended warrant as compared to the original warrant, both valued as of the respective amendment dates.
 
On December 31, 2017, the Company recomputed the fair value of its warrant liability of outstanding warrants to purchase an aggregate of 210,000 shares of common stock as $130,000 using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of 73.37% risk-free rate of 2.09%, expected term of 4.07 years, and expected dividends of 0.00%. The Company recorded a gain on the change in fair value of these warrant liabilities of $692,000 during the year ended December 31, 2017.
 
The issuance of common stock in connection with the Private Placement and Public Offering triggered an adjustment to the exercise price of certain warrants originally issued in November 2012 from $55.10 per share to $5.00 per share to $4.00 per share with a corresponding adjustment to the number of shares underlying such warrants from 6,629 shares to 29,034 shares to 36,231 shares. The impact of such adjustment is included in the change in fair value of the warrant liabilities during the year ended December 31, 2017.
 
Warrants that contain exercise reset provisions and contingent consideration liabilities are Level 3 derivative liabilities measured at fair value on a recurring basis using pricing models for which at least one significant assumption is unobservable as defined in ASC 820. The fair value of contingent consideration liabilities that are classified as Level 3 were estimated using a discounted cash flow technique with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC 820. The significant inputs in the Level 3 measurement not supported by market activity include the probability assessments of expected future cash flows related to the acquisitions, appropriately discounted considering the uncertainties associated with the obligation, and as calculated in accordance with the terms of the acquisition agreements. See Note 13 –Commitments and Contingencies for details on the contingent consideration. The development and determination of the unobservable inputs for Level 3 fair value measurements and the fair value calculations are the responsibility of the Company’s Chief Financial Officer and are approved by the Chief Executive Officer.
 
The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities and contingent consideration that are measured at fair value on a recurring basis (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2017
 
2016
 
Warrant Liabilities
 
 
 
 
 
 
 
Beginning balance
 
$
20
 
$
861
 
Change in fair value of warrant liability
 
 
(693)
 
 
(841)
 
Warrant modification expense
 
 
803
 
 
-
 
Ending balance
 
$
130
 
$
20
 
 
 
 
Year Ended December 31,
 
 
 
2017
 
2016
 
Contingent Consideration
 
 
 
 
 
 
 
Beginning balance
 
$
1,816
 
$
17,028
 
Payments of contingent consideration
 
 
(1,851)
 
 
(5,147)
 
Change in fair value of contingent consideration
 
 
35
 
 
(10,065)
 
Ending balance
 
$
-
 
$
1,816
 
 
Assets and liabilities measured at fair value on a recurring basis are as follows (in thousands):
 
 
 
December 31, 2017
 
 
 
 
 
Level 1
 
Level 2
 
Level 3
 
Total Impairments
 
Assets:
 
 
 
 
 
 
 
 
 
Intangible assets
 
$
-
 
$
-
 
$
22,069
 
$
-
 
Goodwill
 
 
-
 
 
-
 
 
1,659
 
 
10,300
 
Total assets
 
$
-
 
$
-
 
$
23,728
 
$
10,300
 
 
 
 
December 31, 2016
 
 
 
 
 
Level 1
 
Level 2
 
Level 3
 
Total Impairments
 
Assets:
 
 
 
 
 
 
 
 
 
Intangible assets
 
$
-
 
$
-
 
$
26,605
 
$
-
 
Goodwill
 
 
-
 
 
-
 
 
11,959
 
 
10,895
 
Total assets
 
$
-
 
$
-
 
$
38,564
 
$
10,895
 
 
 
 
December 31, 2017
 
 
 
Level 1
 
Level 2
 
Level 3
 
Liabilities:
 
 
 
 
 
 
 
 
 
 
Warrant liabilities
 
$
-
 
$
-
 
$
130
 
Total liabilities
 
$
-
 
$
-
 
$
130
 
 
 
 
December 31, 2016
 
 
 
Level 1
 
Level 2
 
Level 3
 
Liabilities:
 
 
 
 
 
 
 
 
 
 
Warrant liabilities
 
$
-
 
$
-
 
$
20
 
Contingent consideration
 
 
-
 
 
-
 
 
1,816
 
Total liabilities
 
$
-
 
$
-
 
$
1,836